Skip to main content
Recombinant granulocyte colony-stimulating factor

Filgrastim Neupogen® / Fraven®

The SHIKARI® Filgrastim portfolio provides quantitative anti-filgrastim antibody analysis with an IFU-defined confirmation workflow.

1
SHIKARI® Kit
96
Tests per kit
1
Analytical Domain
RUO
Research Use Only
Official Matriks Biotek Filgrastim product visual
TRACE & CATCH · FILGRASTIM
Scientific Background

Why Filgrastim is relevant to biological-drug monitoring research

Filgrastim has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗

Mechanism

Molecular Target & Structure

Filgrastim is recombinant human granulocyte colony-stimulating factor (G-CSF) that activates the G-CSF receptor and stimulates production and maturation of neutrophils. Source ↗

Indications

Approved Indications

Authorised uses include reduction of chemotherapy-associated neutropenia, mobilisation of peripheral blood progenitor cells, severe chronic neutropenia and persistent neutropenia in advanced HIV infection in defined settings. EMA source ↗

Regulatory PK Context

Dose-Dependent Serum Exposure

Regulatory pharmacokinetic data demonstrate dose-dependent peak serum concentrations after subcutaneous administration:

3.45 µg/kg SC · maximum serum~4 ng/mL
11.5 µg/kg SC · maximum serum~49 ng/mL
Elimination half-life~3.5 h

Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.

SHIKARI® Kit Portfolio

One verified Filgrastim research assay

SHIKARI® Q-AFA kit, REF FIL-QNS-FRA
Quantitative ADA Kit
SHIKARI® Q-AFA
Quantitative Antibodies to Filgrastim (Fraven®) ELISA with Confirmation
REF: FIL-QNS-FRA

Quantitative ELISA for anti-filgrastim antibodies with an assay-specific confirmation workflow.

Representative Standard Curve
SHIKARI® Q-AFA representative standard curve for illustrative purposes only
96Tests/kit
2–8°CStorage
10–30°CShipment
Quantitative ADASerum / Plasma1-year shelf life
Technical Reference

Verified Specifications at a Glance

KitREFModeAnalyteSampleVolumeTimeAnalytical outputTestsShelf lifeStorageShipping
SHIKARI® Q-AFAFIL-QNS-FRAQuantitativeAnti-filgrastim antibodiesHuman serum / plasma10 µL140 minLOD 2 ng/mL; LOQ 3.125 ng/mL961 year2–8°C10–30°C

Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.

Kit Selection Guide

Match the assay to the research question

01
Quantify anti-filgrastim antibodies
Use FIL-QNS-FRA for a quantitative ADA result.
02
Use confirmation controls
Use FIL-QNS-FRA with the IFU-defined confirmation-reagent workflow.
03
Keep interpretation method-specific
Use FIL-QNS-FRA using the current REF- and lot-specific protocol.
Scientific Literature

Filgrastim Literature and Product-Use Records

Technical Support & Quotations

Planning a Filgrastim research study?

Matrix Biotek can help identify the appropriate Filgrastim assay and prepare regional quotation and delivery information.

Quotation Request

Review your quote list

Your quotation request is sent directly to Matrix Biotek. A confirmation copy will be sent to your institutional email. No payment is taken online. Current regional pricing, availability and delivery information will be provided in the quotation.

Technical Support